Asset profile
Envudeucitinib
Small molecule
Evidence outlook · lead readout
ONWARD1 (NCT06586112) · Plaque Psoriasis
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
ONWARD1 (NCT06586112): Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Systemic Lupus Erythematosus · Phase 2Plaque Psoriasis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
124 competitors in this universe: 10 direct rivals (same mechanism and indication), 2 same-class, 112 same-indication; 33 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Envudeucitinib: this drug | Phase 3 | Small molecule | TYK2 | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| HS-10374 | Phase 3 | Small molecule | TYK2 | ||
| ICP-488 | Phase 3 | Small molecule | TYK2 | ||
| SYHX1901 | Phase 3 | Small molecule | TYK2 | ||
| TQH3906 | Phase 3 | Small molecule | TYK2 | ||
| WD-890 | Phase 3 | Small molecule | TYK2 | ||
| Zasocitinib | Phase 3 | Small molecule | TYK2 | ||
| CMS-D001 | Phase 2/3 | Small molecule | TYK2 | ||
| BMS-986322 | Phase 2 | Small molecule | TYK2 | ||
| CS32582 | Phase 1/2 | Small molecule | TYK2 | ||
| D-2570 | Phase 3 | Small molecule | TYK2 | ||
| GLPG3667 | Phase 2 | Small molecule | TYK2 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 |
…and 109 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.